How Does Medical Device Regulation Perform in the United States and the European Union? A Systematic Review
Open Access
- 31 July 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 9 (7), e1001276
- https://doi.org/10.1371/journal.pmed.1001276
Abstract
Policymakers and regulators in the United States (US) and the European Union (EU) are weighing reforms to their medical device approval and post-market surveillance systems. Data may be available that identify strengths and weakness of the approaches to medical device regulation in these settings. We performed a systematic review to find empirical studies evaluating medical device regulation in the US or EU. We searched Medline using two nested categories that included medical devices and glossary terms attributable to the US Food and Drug Administration and the EU, following PRISMA guidelines for systematic reviews. We supplemented this search with a review of the US Government Accountability Office online database for reports on US Food and Drug Administration device regulation, consultations with local experts in the field, manual reference mining of selected articles, and Google searches using the same key terms used in the Medline search. We found studies of premarket evaluation and timing (n = 9), studies of device recalls (n = 8), and surveys of device manufacturers (n = 3). These studies provide evidence of quality problems in pre-market submissions in the US, provide conflicting views of device safety based largely on recall data, and relay perceptions of some industry leaders from self-surveys. Few studies have quantitatively assessed medical device regulation in either the US or EU. Existing studies of US and EU device approval and post-market evaluation performance suggest that policy reforms are necessary for both systems, including improving classification of devices in the US and promoting transparency and post-market oversight in the EU. Assessment of regulatory performance in both settings is limited by lack of data on post-approval safety outcomes. Changes to these device approval and post-marketing systems must be accompanied by ongoing research to ensure that there is better assessment of what works in either setting. Please see later in the article for the Editors' Summary.Keywords
This publication has 19 references indexed in Scilit:
- Regulation of Medical Devices in the United States and European UnionNew England Journal of Medicine, 2012
- Device regulation in the European Union: response from MHRAThe Lancet, 2012
- Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk DevicesNew England Journal of Medicine, 2011
- Medical device recalls and transparency in the UKBMJ, 2011
- Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device StudiesArchives of Internal Medicine, 2011
- Achieving Meaningful Device SurveillanceJAMA, 2010
- Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular DevicesJama-Journal Of The American Medical Association, 2009
- Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator leadHeart Rhythm, 2007
- Medical device recalls from 2004 to 2006: a focus on Class I recalls.2007
- Medical Device Regulation: An Introduction for the Practicing PhysicianAnnals of Internal Medicine, 2004